News / Publication

— From accelerating spatial multi-omics analysis to virtual perturbation simulations powered by AI agents — biomy Inc. (Head Office: Chuo-ku, Tokyo; President and Representative Director: Teppei Konishi; hereinafter “biomy”) announces that, through technical collaboration with NVIDIA, it is advancing the development of “Virtual Cell,” an AI drug discovery platform aimed at recreating the human tumor microenvironment on computers. In this initiative, biomy is building spatial

– Developing the "Virtual Cell" Multimodal Spatial AI Foundation Model – Biomy, Inc. (hereinafter "Biomy") announces that it has been selected for the "Post-5G Information and Communication Systems Infrastructure Enhancement R&D Project / Development of Competitive Generative AI Foundation Models," promoted by the Ministry of Economy, Trade and Industry (METI) and the New Energy and Industrial Technology Development Organization (NEDO). Biomy's adopted project is titled "Deve

Collaboration will support development of foundation models to predict therapeutic response and enable biomarker discovery from spatial data TOKYO, JAPAN – June, 4, 2026 – Biomy, Inc. (Headquarters: Chuo-ku, Tokyo; CEO: Teppei Konishi; hereinafter “Biomy”), a technology company focused on advancing personalized medicine through AI, today announced a partnership with 10x Genomics (NASDAQ: TXG), a leader in single cell and spatial biology, to develop AI-driven Virtual Cell foun

By developing a support program for evaluating neoadjuvant therapy effectiveness, Chugai and Biomy aim to improve pathology diagnosis throughput and standardize pathologic response assessment, contributing to optimal treatment selection for patients By developing a program that detects features related to prognosis and drug efficacy from the tumor microenvironment, the two companies aim to realize personalized healthcare and maximize the value of pharmaceuticals TOKYO, No